Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 12 815 M
EBIT 2017 3 782 M
Net income 2017 2 085 M
Debt 2017 12 175 M
Yield 2017 -
Sales 2018 13 304 M
EBIT 2018 4 083 M
Net income 2018 2 254 M
Debt 2018 10 312 M
Yield 2018 -
P/E ratio 2017 12,84
P/E ratio 2018 10,94
EV / Sales2017 2,49x
EV / Sales2018 2,26x
Capitalization 19 722 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
05/04Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/20 MYLAN : Launches Generic Trilafon Tablets
04/04 MYLAN NV : Today's Research Reports on Stocks to Watch: Mylan and Pfizer
04/03 HAGENS BERMAN : EpiPen Purchasers Accuse Drug Maker Mylan of Fraud, RICO Enterpr..
03/31 MYLAN : Provides Update on Meridian Medical Technologies', a Pfizer Company, Exp..
03/29 MYLAN : Completes Acquisition of Cold-EEZE® Brand
03/29 MYLAN : Comments on Generic Advair Diskus® Abbreviated New Drug Application
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28 MYLAN : Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer
More news
Sector news : Pharmaceuticals - NEC
03:01a Becton Dickinson to acquire Bard for $24 billion
04/22DJNOVARTIS : Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/21DJFDA OKs Samsung Bioepis's biosimilar version of J&J's Remicade
04/21 Teva's new asthma inhaler poses first competition for GSK's Advair
04/19DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 51,2 $
Spread / Average Target 39%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%19 722
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.57%200 330
NOVARTIS AG-1.08%192 857
MERCK & CO., INC.5.13%169 673
More Results